Pancreatic enzymes (medication)
Pancreatic enzymes, also known as pancreases or pancrelipase and pancreatin, are commercial mixtures of amylase, lipase, and protease. They are used to treat malabsorption syndrome due to certain pancreatic problems. These pancreatic problems may be due to cystic fibrosis, surgical removal of the pancreas, long term pancreatitis, or pancreatic cancer, among others. The preparation is taken by mouth.
Complex of lipase with colipase
|Trade names||Creon, Pancreaze, Pancrex, others|
|CompTox Dashboard (EPA)|
Common side effects include vomiting, abdominal pain, constipation, and diarrhea. Other side effects include perianal irritation and high blood uric acid. The enzymes are from pigs. Use is believed to be safe during pregnancy. The components are digestive enzymes similar to those normally produced by the human pancreas. They help the person digest fats, starches, and proteins.
Pancreatic enzymes have been used as medications since at least the 1800s. They are on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. In the United Kingdom a typical month's supply costs the NHS about £12.93 to £47.55 as of 2019. In the United States the wholesale cost of this amount is about US$300 to US$900. In 2017, it was the 275th most commonly prescribed medication in the United States, with more than one million prescriptions.
Pancrelipases are generally a first line approach in treatment of exocrine pancreatic insufficiency and other digestive disorders, accompanying cystic fibrosis, complicating surgical pancreatectomy, or resulting from chronic pancreatitis. The formulations are generally hard capsules filled with gastro-resistant granules. Pancrelipases and pancreatins are similar, except pancrelipases has an increased lipase component.
Pancreatin is a mixture of several digestive enzymes produced by the exocrine cells of the pancreas. It is composed of amylase, lipase and protease. This mixture is used to treat conditions in which pancreatic secretions are deficient, such as surgical pancreatectomy, pancreatitis and cystic fibrosis. It has been claimed to help with food allergies, celiac disease, autoimmune disease, cancer and weight loss. Pancreatin is sometimes called "pancreatic acid", although it is neither a single chemical substance nor an acid.
Pancreatin contains the pancreatic enzymes trypsin, amylase and lipase. A similar mixture of enzymes is sold as pancrelipase, which contains more active lipase enzyme than does pancreatin. The trypsin found in pancreatin works to hydrolyze proteins into oligopeptides; amylase hydrolyzes starches into oligosaccharides and the disaccharide maltose; and lipase hydrolyzes triglycerides into fatty acids and glycerols. Pancreatin is an effective enzyme supplement for replacing missing pancreatic enzymes, and aids in the digestion of foods in cases of pancreatic insufficiency.
Pancreatin reduces the absorption of iron from food in the duodenum during digestion.
Though never reported there is a theoretical risk of a viral infection as they are from pigs.
Society and cultureEdit
Longstanding pancreatic enzyme replacement products (PERPs)—some in use for a century or more—fell under a 2006 FDA requirement that pharmaceutical companies with porcine-derived PERP products submit a New Drug Application (NDA) for each; Creon (AbbVie Inc.), the first of the commercial PERP products approved after the FDA directive, reached market in 2009.
The specific requirement and reasoning for the FDA directive was that manufacturers submit a Risk Evaluation and Mitigation Strategy (REMS) and Medication Guide to ensure patients are adequately informed regarding potential risks associated with administration of high doses of porcine-derived PERP products, especially with regard to "the theoretical risk of transmission of viral disease from pigs to patients", the risk of which (alongside other off-target effects) is reduced by patient adherence to label dosing instructions.
- "Pancrelipase". The American Society of Health-System Pharmacists. Archived from the original on 18 January 2017. Retrieved 8 January 2017.
- "Pancreatin". The American Society of Health-System Pharmacists. Archived from the original on 18 January 2017. Retrieved 8 January 2017.
- British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 82–83. ISBN 9780857111562.
- Stuhan, Mary Ann (2013). Understanding Pharmacology for Pharmacy Technicians. ASHP. p. 597. ISBN 9781585283606. Archived from the original on 2017-09-14.
- Bagchi, Debasis; Swaroop, Anand; Bagchi, Manashi (2015). Genomics, Proteomics and Metabolomics in Nutraceuticals and Functional Foods. John Wiley & Sons. p. 274. ISBN 9781118930465. Archived from the original on 2017-09-18.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 96–97. ISBN 9780857113382.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Pancrelipase Lipase; Pancrelipase Protease; Pancrelipase Amylase - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Whitehead, A. M. (February 1988). "Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations". Pharmaceutisch Weekblad Scientific Edition. 10 (1): 12–16. doi:10.1007/BF01966429.
- Löhr, Johannes-Matthias; Hummel, Frank M.; Pirilis, Konstantinos T.; Steinkamp, Gregor; Körner, Andreas; Henniges, Friederike (September 2009). "Properties of different pancreatin preparations used in pancreatic exocrine insufficiency". European Journal of Gastroenterology & Hepatology. 21 (9): 1024–1031. doi:10.1097/MEG.0b013e328328f414. PMID 19352190.
- Smith, R. Sephton (August 1965). "Iron Deficiency and Iron Overload". Archives of Disease in Childhood. 40 (212): 343–363. doi:10.1136/adc.40.212.343. PMC 2019287. PMID 14329251.
- BAINES, M G; CAI, F; BACKMAN, H A (November 1990). "Adsorption and Removal of Protein Bound to Hydrogel Contact Lenses". Optometry and Vision Science. 67 (11): 807–810. doi:10.1097/00006324-199011000-00003. PMID 2250887.
- Lloyd-Still, JD; Beno, DW; Kimura, RM (June 1999). "Cystic fibrosis colonopathy". Current Gastroenterology Reports. 1 (3): 231–7. doi:10.1007/s11894-999-0040-4. PMID 10980955.
- Schibli, S; Durie, PR; Tullis, ED (November 2002). "Proper usage of pancreatic enzymes". Current Opinion in Pulmonary Medicine. 8 (6): 542–6. doi:10.1097/00063198-200211000-00010. PMID 12394164.
- "CREON® (pancrelipase) Delayed-Release Capsule | Official Website". www.creon.com. Retrieved 2019-10-10.
- U.S. Food and Drug Administration (May 7, 2009). "FDA Approves Pancreatic Enzyme Replacement Product for Marketing in United States: Creon designed to help those with cystic fibrosis, others with exocrine pancreatic insufficiency". News & Events, FDA News Release. Retrieved July 20, 2014.